Cara Therapeutics Inc. (NASDAQ: CARA) has announced its operational and financial results for the third quarter ending September 30, 2021, in which revenue was $20.3 million...
Cara Therapeutics Inc. (NASDAQ:CARA) and Vifor Pharma have announced that the US FDA has accepted and given Priority Review for KORSUVA™’s New Drug Application (NDA). KORSUVA...
Cara Therapeutics Inc (NASDAQ:CARA) expanded its board by recruiting Dr. Susan Shiff. Commenting on her induction into the board, CEO and President of Cara, Derek Chalmers...
Cara Therapeutics Inc (NASDAQ:CARA) is on track to provide topline data for the pivotal KALM-2 Phase 3 clinical trial of KORSUVA injection in Q2 2020. The...